Decision Support & Provider Education
Streamlined Reports and Result Interpretation
Our reports provide information about your patient’s genomic findings and biomarkers and their associated targeted therapies and clinical trial options when available.
All Foundation Medicine CGP reports include a “Report Highlights” section on the first page, which summarizes actionable results in one easy-to-find bulletin-style box. Reports for FoundationOne®Liquid CDx also include historic patient findings from earlier Foundation Medicine tests, which allow you to follow your patients’ genomic profiles across the duration of their disease.
FoundationOne®CDx and FoundationOne®Liquid CDx Report Features
Summary of all actionable results in one easy-to-find bulletin-style box on the first page of the report. Personalized for each patient, helping you focus on the key results to inform your patient’s treatment plan.
THERAPIES WITH CLINICAL BENEFIT & POTENTIAL RESISTANCE
Therapies may be matched to patient genomic alterations based on clinical guidelines and/or published literature. Therapy resistance based on your patient’s genomic profile will also be indicated.
FDA-APPROVED CDx CLAIMS
Reports include a list of FDA-approved companion diagnostics, if available, to identify patients who may be eligible for treatment with associated therapies.
CLINICAL TRIAL OPTIONS
Detailed information about the clinical trials your patient has been matched to, ranked for the patient based on location and trial phase.
Medical Inquiries: Result Interpretation
Discuss patient results with the Medical Affairs team at Foundation Medicine. This robust on-call program is covered by internal experts such as the Medical Science Liaison (MSL) team or by internal and external oncologists who are subject matter experts and consultants for Foundation Medicine.
Inquiries can be escalated via phone, email, or through the “Ask an Expert” portal
Our team responds to over 200 inquiries per month†
Inquiries are handled within 24-48 hours in 95% of cases†
Questions? We’re Here to Help
Please contact our client services team by phone at
+1(888) 988-3639 or by email at the link below.
*On FoundationOne Liquid CDx, MSI status will be reported for samples determined to have high microsatellite instability as a laboratory professional service which is not reviewed or approved by the FDA.
†As of May 2021
Important Safety Information
FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com.
FoundationOne Liquid CDx
FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.